Log in to search using one of your social media accounts:

 

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy  of Patients with CLL with Mutated IGHV and Without Deletion 17p

CLL, Chemotherapy, Ibrutinib, Frontline Treatment, Mutated IGHV
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Curative treatment of acute myeloid leukemia (AML) is based on one or two cycles of remission induction chemotherapy followed by consolidation chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in those patients who enter complete remission (CR).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This article is protected by copyright. All rights reserved.
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: Comprehensive Review Source Type: research
Publication date: Available online 7 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Fernando Cabanillas, Bijal Shah The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving since the discovery of its 2 major forms, the germinal center B-like (GCB) and activated B-cell (ABC) types. Although the reference standard for the identification of these cell types is considered gene expression profiling (GEP), currently the only method commercially available is immunohistochemistry (IHC). The application of various IHC-based algorithms and their correlation with GEP and clinical ou...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions Long-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous and durable remission can be achieved with intermediate intensity therapy. Maintenance rituximab appears to contribute to these excellent outcomes. Teaser VcR-CVAD with maintenance rituximab is an intermediate-intensity regimen for older and younger mantle cell lymphoma (MCL) patients. Thirty patients were treated, with primary end point of response and secondary endpoints of progression-free and overall survival. After a median follow-up of 7.8 years, no relapses were o...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Overall effectiveness and tolerability outcomes were similar between modified hyperCVAD and bortezomib-hyperCAD, with both regimens demonstrating an impressive response rate among refractory and heavily pre-treated patients with relapsed MM. Teaser Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our data seem to confirm the value of FLAG-Ida in this setting and might suggest its best usage as bridge therapy for patients awaiting allotransplantation. Micro-Abstract Allotransplant is crucial for improving survival in refractory/first relapsed AML patients. An overall response was achieved in 48 patients (44% of the whole group) with FLAG-Ida chemotherapy approach. 24 of 48 responders underwent allotransplantation obtaining a median OS of 60 months.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and ∼90% of patients who present with early-stage (stage I-II) disease and 70% of patients who present with late-stage disease will be cured with standard frontline treatment. For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy, fo llowed by autologous transplantation (autoSCT). Although this approach will cure a significant proportion of patients, upto 50% of patients will experience disease progression after autoSCT, and this population has historically had a very poor prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and approximately 90% of patients who present with early stage (I-II) disease (1) and 70% of patients who present with late-stage disease will be cured with standard frontline treatment(2). For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy followed by autologous transplant (autoSCT). While this approach will cure a significant proportion of patients, up to 50% of patients will experience disease progression after autoSCT(3), and this population has historically had a very poor prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
VcR-CVAD with maintenance rituximab is an intermediate-intensity regimen for older and younger mantle cell lymphoma (MCL) patients. Thirty patients were treated, with primary end point of response and secondary endpoints of progression-free and overall survival. After a median follow-up of 7.8 years, no relapses were observed beyond 6 years. VcR-CVAD has long-term outcomes comparable with more intensive chemotherapy regimens.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of patients demonstrating an overall response rate of 42%.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Chemotherapy | Leukemia | Lymphoma | Myeloma